ArticleChinese journal of cancer research = Chung-kuo yen cheng yen chiu2021
Esophageal cancer: Epidemiology, risk factors and screening.
Article in Chinese journal of cancer research = Chung-kuo yen cheng yen chiu, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 127 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
127 citing papers in PubMed, 3 syntheses or guidelines pooled it, 204 citations in OpenAlex.
- Associations of PD-L1 expression status, tumor histology and patient ethnic background with immunotherapy outcomes in patients with advanced esophageal cancer.Frontiers in pharmacology · 2026Pooled it
- Impact of negative lymph node removal on survival in esophageal cancer: a systematic review and meta-analysis.BMC surgery · 2025Pooled it
- Clinical benefits of PD-1 inhibitors in specific subgroups of patients with advanced esophageal squamous cell carcinoma: a systematic review and meta-analysis of phase 3 randomized clinical trials.Frontiers in immunology · 2023Pooled it
- Spatial proteomic profiling elucidates immune determinants of neoadjuvant chemo-immunotherapy in esophageal squamous cell carcinoma.Oncogene · 2024Trial
- Trial
- Inhibition of the AT-Hook DNA-Binding Domain Attenuates HMGA2-Mediated Epithelial Mesenchyme Transition in Esophageal Cancer Cells.International journal of molecular sciences · 2026Article
- Increased performance of thoracoscopic, mediastinoscopic, and robotic esophageal cancer surgeries in Japan: a decade-long nationwide claims-based analysis (2014-2023).Surgery today · 2026Article
- HK2/VDAC1 Axis Regulates Malignant Progression of Esophageal Squamous Cell Carcinoma.Cancer medicine · 2026Article
- A Noncanonical RNA-Binding Function of NQO1 Drives Angiogenesis in Esophageal Squamous Cell Carcinoma via Extracellular Vesicle-Mediated AGRN Transfer.Cancer research · 2026Article
- Identification of macrophage polarization-related genes for esophageal cancer risk: a multi-omics Mendelian randomization analysis.Clinical epigenetics · 2026Article
- AI-driven multi-omics drug repurposing nominates AZD7762 as a multitarget inhibitor of IL22RA1 and FAM221A in esophageal squamous cell carcinoma.NPJ precision oncology · 2026Article
- miR-3678-3p Promotes Esophageal Squamous Cell Carcinoma Progression by Regulating Phosphatase and Tensin Homolog.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2026Article
- Single-Cell RNA Sequencing Identifies a Distinct Epithelial Subpopulation Driving Resistance to Neoadjuvant Chemoimmunotherapy in Esophageal Squamous Cell Carcinoma.Biological procedures online · 2026Article
- Hospital-based patterns of esophageal and gastric cancer cases at a major tertiary referral center in Kabul, Afghanistan: a retrospective case series.BMC cancer · 2026Article
- Computational identification of rare pathogenic genomic variants in esophageal cancer markers: Transcript-level analysis, sequence-based insights, and structural-functional impacts of non-synonymous SNPs.Biochemistry and biophysics reports · 2026Article
- Coexistence of Friedreich's Ataxia and Esophageal Cancer: A Case Report.Clinical case reports · 2026Article
- Trends, patterns, and risk factors of esophageal cancer mortality in China, 2008-2021: A National Mortality Surveillance System data analysis.Journal of advanced research · 2026Article
- Multivariate integrated predictive model for 1-year mortality risk prognosis in patients undergoing esophageal cancer resection: establishment and validation.BMC surgery · 2026Article
- Lactylation in cancer: molecular mechanisms and advances in clinical study.Molecular cancer · 2026Review
- Autoimmune GFAP astrocytopathy associated with sintilimab immunotherapy in a patient with esophageal squamous cell carcinoma: a case report and literature review.Frontiers in oncology · 2026Article
67 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
More than 600,000 people are diagnosed with esophageal cancer (EC) every year globally, and the five-year survival rate of EC is less than 20%. Two common histological subtypes of EC, esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC), have great geographical variations in incidence rates. About half of the world's EC was diagnosed in China and a majority of which belong to ESCC. Globally, the overall incidence rate of EC is decreasing. In some high-risk Asian regions, such as China, the incidence rate of ESCC has generally declined, potentially due to economic growth and improvement of diet habits. In some European high-income countries and the United States, the decline is mainly attributed to the decrease in smoking and drinking. The risk factors of EC are not well understood, and the importance of environmental and genetic factors in the pathogenesis is also unclear. The incidence and mortality of advanced EC can be reduced through early diagnosis and screening. White light endoscopy is still the gold standard in the current screening technology. This article reviews the epidemiology, risk factors, and screening strategies of EC in recent years to help researchers determine the most effective management strategies to reduce the risk of EC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.